Theranostics Health is a proteomics-based diagnostics company that provides research services to drug development companies and is developing diagnostic tests to enable personalized cancer therapies tailored to each patient’s tumor. Our technologies utilize Laser Capture Microdissection (LCM) and Reverse-phase Protein MicroArrays (RPMA) assays to accurately measure drug targets and their signaling pathways within tumor cells. Our technologies are also of particular use for companies developing Molecular Targeted Therapies and allow insights into the phospho-activation status of drug targets, their downstream pathways and potential survival mechanisms or pathways within targeted cell populations and are utilized in a translational research manner from preclinical SAR-type studies through to Phase II clinical trials. Theranostics Health is also a CAP-CLIA laboratory service provider of clinical tests that focus upon drug target and pathway signaling activation which enable physicians to tailor optimized therapies for patients based on the biomarker profile of each patient’s unique cancer proteome. Our currently available assay panel, the TheraLink™ HER Family Assay, measures the total amount and activation (phosphorylation) status of the therapeutically relevant EGFR, HER2 and HER3 receptor family, and their downstream signaling pathways in primary and metastatic breast cancers.